Na+/H+ exchanger inhibitor cariporide attenuates the mitochondrial Ca2+ overload and PTP opening

Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3517-23. doi: 10.1152/ajpheart.00483.2006. Epub 2007 Sep 28.

Abstract

The Na(+)/H(+) exchanger (NHE) inhibitor cariporide has a cardioprotective effect in various animal models of myocardial ischemia-reperfusion. Recent studies have suggested that cariporide interacts with mitochondrial Ca(2+) overload and the mitochondrial permeability transition (MPT); however, the precise mechanisms remain unclear. Therefore, we examined whether cariporide affects mitochondrial Ca(2+) overload and MPT. Isolated adult rat ventricular myocytes were used to study the effects of cariporide on hypercontracture induced by ouabain or phenylarsine oxide (PAO). Mitochondrial Ca(2+) concentration ([Ca(2+)](m)) and the mitochondrial membrane potential (DeltaPsi(m)) were measured by loading myocytes with rhod-2 and JC-1, respectively. We also examined the effect of cariporide on the MPT using tetramethylrhodamine methyl ester (TMRM) and oxidative stress generated by laser illumination. Cariporide (1 microM) prevented ouabain-induced hypercontracture (from 40 +/- 2 to 24 +/- 2%, P < 0.05) and significantly attenuated ouabain-induced [Ca(2+)](m) overload (from 149 +/- 6 to 121 +/- 5% of the baseline value, P < 0.05) but did not affect DeltaPsi(m). These results indicate that cariporide attenuates the [Ca(2+)](m) overload without the accompanying depolarization of DeltaPsi(m). Moreover, cariporide increased the time taken to induce the MPT (from 79 +/- 11 to 137 +/- 20 s, P < 0.05) and also attenuated PAO-induced hypercontracture (from 59 +/- 3 to 50 +/- 4%, P < 0.05). Our data indicate that cariporide attenuates [Ca(2+)](m) overload and MPT. Thus these effects might potentially contribute to the mechanisms of cardioprotection afforded by NHE inhibitors.

MeSH terms

  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Arsenicals / pharmacology
  • Calcium / metabolism*
  • Cardiotonic Agents / pharmacology
  • Decanoic Acids / pharmacology
  • Glyburide / pharmacology
  • Guanidines / pharmacology*
  • Heart Ventricles / drug effects
  • Heart Ventricles / metabolism
  • Hydroxy Acids / pharmacology
  • In Vitro Techniques
  • Male
  • Membrane Potential, Mitochondrial / drug effects
  • Mitochondria, Heart / drug effects*
  • Mitochondria, Heart / metabolism
  • Mitochondrial Membrane Transport Proteins / drug effects*
  • Mitochondrial Membrane Transport Proteins / metabolism
  • Mitochondrial Permeability Transition Pore
  • Myocardial Contraction / drug effects
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Ouabain / pharmacology
  • Oxidative Stress / drug effects
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels / drug effects
  • Potassium Channels / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Sodium / metabolism
  • Sodium-Hydrogen Exchangers / antagonists & inhibitors*
  • Sodium-Hydrogen Exchangers / metabolism
  • Sulfones / pharmacology*
  • Time Factors

Substances

  • Anti-Arrhythmia Agents
  • Arsenicals
  • Cardiotonic Agents
  • Decanoic Acids
  • Guanidines
  • Hydroxy Acids
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • Potassium Channel Blockers
  • Potassium Channels
  • Sodium-Hydrogen Exchangers
  • Sulfones
  • mitochondrial K(ATP) channel
  • oxophenylarsine
  • Ouabain
  • 5-hydroxydecanoic acid
  • cariporide
  • Sodium
  • Glyburide
  • Calcium